<?xml version='1.0' encoding='utf-8'?>
<document id="27433344"><sentence text="Snapshot of the prescribing practice for the clopidogrel and esomeprazole coprescription and cost evaluation of the application guidelines."><entity charOffset="45-56" id="DDI-PubMed.27433344.s1.e0" text="clopidogrel" /><entity charOffset="61-73" id="DDI-PubMed.27433344.s1.e1" text="esomeprazole" /><pair ddi="false" e1="DDI-PubMed.27433344.s1.e0" e2="DDI-PubMed.27433344.s1.e0" /><pair ddi="false" e1="DDI-PubMed.27433344.s1.e0" e2="DDI-PubMed.27433344.s1.e1" /></sentence><sentence text="The antiplatelet clopidogrel and the proton pump inhibitor esomeprazole demonstrate a pharmacokinetic interaction through CYP2C19 that could translate into clinical inefficacy of clopidogrel"><entity charOffset="17-28" id="DDI-PubMed.27433344.s2.e0" text="clopidogrel" /><entity charOffset="59-71" id="DDI-PubMed.27433344.s2.e1" text="esomeprazole" /><entity charOffset="179-190" id="DDI-PubMed.27433344.s2.e2" text="clopidogrel" /><pair ddi="false" e1="DDI-PubMed.27433344.s2.e0" e2="DDI-PubMed.27433344.s2.e0" /><pair ddi="false" e1="DDI-PubMed.27433344.s2.e0" e2="DDI-PubMed.27433344.s2.e1" /><pair ddi="false" e1="DDI-PubMed.27433344.s2.e0" e2="DDI-PubMed.27433344.s2.e2" /><pair ddi="false" e1="DDI-PubMed.27433344.s2.e1" e2="DDI-PubMed.27433344.s2.e1" /><pair ddi="false" e1="DDI-PubMed.27433344.s2.e1" e2="DDI-PubMed.27433344.s2.e2" /></sentence><sentence text=" No medical consensus as to their coprescription has been reached, and different guidelines are available" /><sentence text=" We evaluated the prescribing practices at the Geneva University Hospitals (HUG) by measuring whether the coprescription was staggered as suggested by experts" /><sentence text=" We estimated the financial impact of different implementation guidelines" /><sentence text=" We used the HUG electronic patient records to follow the physicians' prescriptions and the administration by nurses from January 2013 to April 2014" /><sentence text=" We performed a time series analysis to assess 15Â years of proton pump inhibitors (PPIs) and antiplatelet drug use" /><sentence text=" &quot;Extra costs&quot; were calculated assuming that clopidogrel or esomeprazole would replace prasugrel or ticagrelor and pantoprazole or ranitidine, respectively"><entity charOffset="45-56" id="DDI-PubMed.27433344.s8.e0" text="clopidogrel" /><entity charOffset="60-72" id="DDI-PubMed.27433344.s8.e1" text="esomeprazole" /><entity charOffset="87-96" id="DDI-PubMed.27433344.s8.e2" text="prasugrel" /><entity charOffset="100-110" id="DDI-PubMed.27433344.s8.e3" text="ticagrelor" /><entity charOffset="115-127" id="DDI-PubMed.27433344.s8.e4" text="pantoprazole" /><entity charOffset="131-141" id="DDI-PubMed.27433344.s8.e5" text="ranitidine" /><pair ddi="false" e1="DDI-PubMed.27433344.s8.e0" e2="DDI-PubMed.27433344.s8.e0" /><pair ddi="false" e1="DDI-PubMed.27433344.s8.e0" e2="DDI-PubMed.27433344.s8.e1" /><pair ddi="false" e1="DDI-PubMed.27433344.s8.e0" e2="DDI-PubMed.27433344.s8.e2" /><pair ddi="false" e1="DDI-PubMed.27433344.s8.e0" e2="DDI-PubMed.27433344.s8.e3" /><pair ddi="false" e1="DDI-PubMed.27433344.s8.e0" e2="DDI-PubMed.27433344.s8.e4" /><pair ddi="false" e1="DDI-PubMed.27433344.s8.e0" e2="DDI-PubMed.27433344.s8.e5" /><pair ddi="false" e1="DDI-PubMed.27433344.s8.e1" e2="DDI-PubMed.27433344.s8.e1" /><pair ddi="false" e1="DDI-PubMed.27433344.s8.e1" e2="DDI-PubMed.27433344.s8.e2" /><pair ddi="false" e1="DDI-PubMed.27433344.s8.e1" e2="DDI-PubMed.27433344.s8.e3" /><pair ddi="false" e1="DDI-PubMed.27433344.s8.e1" e2="DDI-PubMed.27433344.s8.e4" /><pair ddi="false" e1="DDI-PubMed.27433344.s8.e1" e2="DDI-PubMed.27433344.s8.e5" /><pair ddi="false" e1="DDI-PubMed.27433344.s8.e2" e2="DDI-PubMed.27433344.s8.e2" /><pair ddi="false" e1="DDI-PubMed.27433344.s8.e2" e2="DDI-PubMed.27433344.s8.e3" /><pair ddi="false" e1="DDI-PubMed.27433344.s8.e2" e2="DDI-PubMed.27433344.s8.e4" /><pair ddi="false" e1="DDI-PubMed.27433344.s8.e2" e2="DDI-PubMed.27433344.s8.e5" /><pair ddi="false" e1="DDI-PubMed.27433344.s8.e3" e2="DDI-PubMed.27433344.s8.e3" /><pair ddi="false" e1="DDI-PubMed.27433344.s8.e3" e2="DDI-PubMed.27433344.s8.e4" /><pair ddi="false" e1="DDI-PubMed.27433344.s8.e3" e2="DDI-PubMed.27433344.s8.e5" /><pair ddi="false" e1="DDI-PubMed.27433344.s8.e4" e2="DDI-PubMed.27433344.s8.e4" /><pair ddi="false" e1="DDI-PubMed.27433344.s8.e4" e2="DDI-PubMed.27433344.s8.e5" /></sentence><sentence text=" Only 10" /><sentence text="8% of the patient medical orders for the clopidogrel and esomeprazole coprescription specified to stagger the administration, 12"><entity charOffset="41-52" id="DDI-PubMed.27433344.s10.e0" text="clopidogrel" /><entity charOffset="57-69" id="DDI-PubMed.27433344.s10.e1" text="esomeprazole" /><pair ddi="false" e1="DDI-PubMed.27433344.s10.e0" e2="DDI-PubMed.27433344.s10.e0" /><pair ddi="false" e1="DDI-PubMed.27433344.s10.e0" e2="DDI-PubMed.27433344.s10.e1" /></sentence><sentence text="6% specified a concomitant coprescription, and 76" /><sentence text="6% had no clear information" /><sentence text=" A high rate of 49" /><sentence text="6% of the nurses staggered the clopidogrel and esomeprazole coprescription when no clear information was given"><entity charOffset="31-42" id="DDI-PubMed.27433344.s14.e0" text="clopidogrel" /><entity charOffset="47-59" id="DDI-PubMed.27433344.s14.e1" text="esomeprazole" /><pair ddi="false" e1="DDI-PubMed.27433344.s14.e0" e2="DDI-PubMed.27433344.s14.e0" /><pair ddi="false" e1="DDI-PubMed.27433344.s14.e0" e2="DDI-PubMed.27433344.s14.e1" /></sentence><sentence text=" We found a statistically significant decrease in clopidogrel use after the publication of the OCLA (Omeprazole-CLopidogrel-Aspirin) study and a significant increase in the trend of esomeprazole"><entity charOffset="50-61" id="DDI-PubMed.27433344.s15.e0" text="clopidogrel" /><entity charOffset="95-99" id="DDI-PubMed.27433344.s15.e1" text="OCLA" /><entity charOffset="182-194" id="DDI-PubMed.27433344.s15.e2" text="esomeprazole" /><pair ddi="false" e1="DDI-PubMed.27433344.s15.e0" e2="DDI-PubMed.27433344.s15.e0" /><pair ddi="false" e1="DDI-PubMed.27433344.s15.e0" e2="DDI-PubMed.27433344.s15.e1" /><pair ddi="false" e1="DDI-PubMed.27433344.s15.e0" e2="DDI-PubMed.27433344.s15.e2" /><pair ddi="false" e1="DDI-PubMed.27433344.s15.e1" e2="DDI-PubMed.27433344.s15.e1" /><pair ddi="false" e1="DDI-PubMed.27433344.s15.e1" e2="DDI-PubMed.27433344.s15.e2" /></sentence><sentence text=" Alternative treatments to avoid this interaction are cost ineffective or offer therapeutic options of lesser quality" /><sentence text=" We observed a high rate of 56" /><sentence text="2% of the clopidogrel and esomeprazole coprescription in our hospital and can therefore not ignore the PK/PD interaction"><entity charOffset="10-21" id="DDI-PubMed.27433344.s18.e0" text="clopidogrel" /><entity charOffset="26-38" id="DDI-PubMed.27433344.s18.e1" text="esomeprazole" /><pair ddi="false" e1="DDI-PubMed.27433344.s18.e0" e2="DDI-PubMed.27433344.s18.e0" /><pair ddi="false" e1="DDI-PubMed.27433344.s18.e0" e2="DDI-PubMed.27433344.s18.e1" /></sentence><sentence text=" The most common prescription practice was to not specify the time frame of administration, which was translated by nurses in 49" /><sentence text="6% of the cases to a scheduled staggered coprescription of clopidogrel and esomeprazole"><entity charOffset="59-70" id="DDI-PubMed.27433344.s20.e0" text="clopidogrel" /><entity charOffset="75-87" id="DDI-PubMed.27433344.s20.e1" text="esomeprazole" /><pair ddi="false" e1="DDI-PubMed.27433344.s20.e0" e2="DDI-PubMed.27433344.s20.e0" /><pair ddi="false" e1="DDI-PubMed.27433344.s20.e0" e2="DDI-PubMed.27433344.s20.e1" /></sentence><sentence text=" As long as no consensus has been reached, the medical orders time frame information should be mandatory to allow a clear and harmonious staggering strategy" /><sentence text="" /></document>